ESMO ADVANCED COURSE PROGRAMME
INNOVATION AND EMERGING KNOWLEDGE IN COLORECTAL CANCER
Paris, France
8-9 May 2020

CO-CHAIRS: Julien Taieb, France
Elena Elez, Spain

SPEAKERS: Jean-Baptiste Bachet, France
Rodrigo Dienstmann, Spain
Erika Martinelli, Italy
Dominik Modest, Germany
Clara Montagut Viladot, Spain
Andrea Sartore Bianchi, Italy
Jenny Seligmann, United Kingdom

LEARNING OBJECTIVES

• To learn the biological basis and characterization of Colorectal Cancer (CRC)
• To understand the essentials in the assessment and the value of multidisciplinary management of patients with CRC
• To learn how to integrate and to sequence the available therapies in the management of a patient with advanced CRC integrating molecular and clinical information including direct exposure to real clinical scenarios
• To learn and discuss about future advances in diagnose and treatment of CRC

Friday, 8 May 2020

09:00-09:20 Welcome and course overview
         Julien Taieb, FR and Elena Elez, ES

09:20-10:50 Session 1
Biological basis and characterization of CRC

25’ Genomic characterization of CRC
       Andrea Sartore Bianchi, IT

25’ Stroma as a hallmark in CRC
       Rodrigo Dienstmann, ES

25’ Role of microbiota in CRC
       Elena Elez, ES

15’ Discussion
     Faculty
10:50-11:20  Coffee break

11:20-13:20  Session 2
Therapeutic approach in the early disease

25’    Optimizing perioperative treatment in rectal cancer
Jean-Baptiste Bachet, FR

25’    Is there a room for neoadjuvant treatment on colon cancer?
Jenny Seligmann, UK

25’    Potentials of liquid biopsy in the early stage
Clara Montagut Viladot, ES

15’    The Updated Guidelines of Colon Cancer
Julien Taieb, FR

30’    Discussion
Faculty

13:20-14:20  Lunch

14:20-15:35  Session 3
How to manage specific situations

20’    State-of-the-art treatment of left sided RAS/BRAF native CRC. Must we consider and assess clonal evolution?
Jean-Baptiste Bachet, FR

20’    Right sided CRC as an entity: Prognostic and Therapeutic implications
Dominik Modest, DE

20’    How to assess treatment benefit in refractory treatments
Erika Martinelli, IT

15’    Discussion
Faculty

15:35-16:15  Keynote lecture
Integrating data in CRC using Artificial Intelligence
Rodrigo Dienstmann, ES

16:15-16:45  Coffee break

16:45-18:00  Session 4
Novel therapies

20’    Targeting MAP kinase pathway
Elena Elez, ES

20’    Low Prevalence Molecular aberrations in CRC
Clara Montagut Viladot, ES
Appointments:

- Immunotherapy strategies in CRC
  Julien Taieb, FR
- Discussion
  Faculty
- Networking dinner

Saturday, 9 May 2020

9:00-12:30 Workshop sessions
Three parallel workshops sessions with “20” delegates in each group (delegates will attend all 3 sessions on a rotation basis)

  15’ Introduction of the topic on real examples presented by speakers
  40’ Discussion
  5’ Break

Workshop 1
Management of liver limited disease beyond front line treatment
Jean-Baptiste Bachet, FR
Jenny Seligmann, UK

Workshop 2
Identifying advanced CRC patients for comprehensive molecular profiling: Who and When
Clara Montagut Viladot, ES
Dominik Modest, DE

11:00-11:30 Coffee break

Workshop 3
Innovative trial Designs in advanced CRC
Erika Martinelli, IT
Rodrigo Dienstmann, ES

12:30-13:00 Feedback on the workshops from each group

13:00-13:30 Synthesis and wrap-up
Julien Taieb, FR and Elena Elez, ES

13:30-14:30 Lunch